Related Experiment Video
Updated: Jan 25, 2026

Author Spotlight: Accelerating Cognitive Impairment Research in Mice Through Stereotaxic Injection and Cost-Effective Dyes
Published on: July 19, 2024
Preliminary results of the CeraflexTM PDA occluder and device behaviour during releasing
Serdar Epçaçan1, Mustafa Orhan Bulut2, İlker Kemal Yücel2
1Department of Pediatric Cardiology,University of Health Sciences,Van Training and Research Hospital, Van,Turkey.
Insights
The CeraFlexTM PDA occluder is safe and effective for closing patent ductus arteriosus. Its unique system ensures stable device placement in most cases, with minimal complications.
Area of Science:
- Cardiovascular Medicine
- Medical Devices
- Pediatric Cardiology
Background:
- Patent ductus arteriosus (PDA) is a common congenital heart defect.
- Transcatheter device closure is an alternative to surgical intervention.
- The CeraFlexTM PDA occluder offers a novel approach to PDA closure.
Purpose of the Study:
- To prospectively evaluate the efficacy of the CeraFlexTM PDA occluder.
- To assess device behavior patterns during and after release.
- To determine the safety and stability of the CeraFlexTM device.
Main Methods:
- Prospective study of 21 patients undergoing PDA closure.
- Patients' median age was 1.2 years (range: 6 months-28 years).
- Antegrade delivery approach with focus on device behavior during release.
Main Results:
- Device position remained stable after release in 91% of patients.
- Minor release difficulties occurred in 29% of cases.
- One case of late device embolization required retrieval and reimplantation.
Conclusions:
- The CeraFlexTM PDA occluder is safe and efficacious for PDA closure.
- The device's unique delivery system generally ensures stable post-release positioning.
- Larger sheath sizes are a potential drawback for device delivery.
Introduction:
The CeraFlexTM PDA occluder is a new flexible device with a unique delivery system that may be beneficial with regard to not changing the device position after releasing. We prospectively evaluate the efficacy of the device and also the device behaviour patterns during release.
Methods:
The study included 21 patients. Their median age was 1.2 years (from 6 months to 28 years) and weight was 9.6 kg (from 5.4 to 82 kg). All of the ducts were conical except one atypical ductus. Median ductal diameter at the pulmonary end was 3.8 mm (from 2.2 to 8.2 mm). The ductus was closed using an antegrade approach, but special attention was paid to the patterns of device behaviour during and just after releasing.
Results:
Three different modes of device behaviour were observed during and just after releasing: (1) Neither difficulty nor change of position in 13 patients (62%), (2) a little difficulty in releasing but no change of position in 6 (29%), and (3) change of the device position in 2 (9%). There was no residual shunt on the next day except in one patient, in whom late device embolisation occurred. The device was retrieved and another, bigger device implanted.
Conclusion:
The CeraFlexTM PDA occlude device seems to be safe and efficacious for patent ductus arteriosus closure. Its unique delivery system generally fixes the device in a stable position that does not change after release (91%). Minor difficulty in releasing is not uncommon; however, the major disadvantage is the need for larger sheaths for delivery.
Related Concept Videos
Energy-releasing Steps of Glycolysis
The first energy-releasing step—the 6th step of glycolysis...
Drugs Affecting Neurotransmitter Release or Uptake
ATP Energy Storage and Release
One example of energy coupling using ATP involves a...
Mnemonic Devices
Acronyms
Acronyms are created by using the initial letters of a series of words to form a new word or phrase. This approach condenses complex information into a single, memorable entity. For example,...
Non-ohmic Devices
Consider a simple circuit consisting of a battery, a diode, and a resistor. A...
In Vitro Drug Release Testing: Overview, Development and Validation

